15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Atara Biotherapeutics Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $10.00 to $13.00, so the covering firms are broadly aligned. The average target of $11.50 sits 50% above the current $7.69. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees revenue growth near -91% this year and 308% next, consensus EPS building from about $-0.20 next quarter toward $1.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Atara Biotherapeutics Inc.
As of Jul, 1 of 2 firms rate ATRA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ATRA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.20
Range $-0.30 – $-0.11 · 2 analysts · -36% YoY
Next period, 2 analysts expect Atara Biotherapeutics Inc to earn $-0.20 a share (range $-0.30 – $-0.11), versus $-0.32 a year earlier. Full-year consensus is $-0.88, growing to $1.27 the year after.
REVENUE · NEXT QUARTER
$366.7K
Range $0 – $1.0M · 2 analysts · -83% YoY
Revenue is expected to reach $366.7K (range $0 – $1.0M), -83.0% year-over-year. Full-year consensus is $2.1M, rising to $45.1M next year.
Top analysts covering Atara Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ATRA.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Hold
No targeton ATRA
Overall win rate
38%
+ Follow
#2
John Newman
Canaccord Genuity · Rank #340
Buy
$13.00+69.1% to target
Overall win rate
30%
+ Follow
#3
IZ
Ilya Zubkov
Freedom Broker
Hold
$10.00+30.0% to target
Coverage
—
+ Follow
#4
TB
Tony Butler
Rodman & Renshaw
Buy
$25.00+225.1% to target
Coverage
—
+ Follow
#5
Salim Syed
Mizuho
Buy
$18.00+134.1% to target
Coverage
—
+ Follow
ATRA stock forecast FAQ
What is ATRA's average 12-month price target?+
The 2 analysts with a live target average $11.50 for Atara Biotherapeutics Inc over the next 12 months, ranging from a $13.00 high to a $10.00 low.
Is ATRA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ATRA?+
The Street-high target is $13.00 (Canaccord Genuity), and the Street-low is $10.00 (Freedom Broker). The average of all 2 active targets is $11.50.
How many Wall Street analysts cover ATRA?+
2 analysts have an active rating on Atara Biotherapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ATRA?+
Among analysts who currently cover ATRA, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #195). Their current call is Hold.
What is Atara Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.20 per share (range $-0.30 – $-0.11) across 2 analysts. Full-year EPS is projected at $-0.88, rising to $1.27 the following year.
How much revenue is Atara Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $366.7K (range $0 – $1.0M). Full-year revenue is projected at $2.1M, growing to $45.1M next year.
Have analysts been upgrading or downgrading ATRA lately?+
As of Jul, 1 of 2 firms rate ATRA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ATRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
